# Part II continuations (40 tokens)

Greedy, and sampling with temperature=0.8, top-k=40, seeds [0, 1, 2] (same settings as Part I).


## Prompt 1: "this study aimed to evaluate the"

**A: random, trainable** (greedy): efficacy of the <unk> <unk> ( <unk> ) , and <unk> ( <unk> ) . <eos> the primary outcome was the <unk> of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk>

- sample seed 0: effects of acute treatment and a standard intervention for the intervention of coronary care ( @ % ) or <unk> ( @ mg ) every placebo . <eos> in the study , the intervention included a total of @ patients
- sample seed 1: effects of three drugs to the first @ mg/kg , and for the first <unk> therapy . <eos> a randomized trial of @-@ @ patients who received a <unk> ( gb ) was followed by @ mg of @ cases
- sample seed 2: effectiveness of <unk> by @ to @ mg vs. @ g per infarction ) . <eos> the intervention consisted of the intervention program in @ hospitals of the <unk> . <eos> a total of @ patients undergoing @ patients who

**B: own skip-gram, frozen** (greedy): efficacy of the intervention of the <unk> of the <unk> <unk> ( <unk> ) in the <unk> <unk> ( <unk> ) . <eos> the primary outcome was the efficacy of the intervention group ( @ ) in the control group

- sample seed 0: effects of acute treatment and a standard intervention therapy , intervention in children receiving adults . <eos> data were evaluated by our study were analyzed at @ years and june @ , @ , and @ ( @ % )
- sample seed 1: effects of a combined a program on to assess whether of chronic and functional disease ( <unk> ) . <eos> we performed a study analysis on clinical outcome , and safety of patients who received a <unk> of @ cases
- sample seed 2: effectiveness of an intervention of an new <unk> <unk> program intervention ( <unk> ) . <eos> prospective , placebo-controlled , study , patients in @ hospitals of the netherlands states in a randomised study and the effectiveness of patients who

**C: GloVe, frozen** (greedy): efficacy of the <unk> of the <unk> of the <unk> of the <unk> of the <unk> of the <unk> of the <unk> . <eos> the aim of this study was to evaluate the efficacy of the <unk> of the <unk>

- sample seed 0: effects of acute obstructive and a composite intervention of the intervention of the treatment that be not associated with patients with major pain were randomized into <unk> . <eos> to assess the effectiveness of life in the treatment group by
- sample seed 1: effects of the management of the different with <unk> , and well the effectiveness of the <unk> of a <unk> trial . <eos> the primary outcome was a <unk> ( mean of patients , @ to @ years ) .
- sample seed 2: effectiveness of <unk> by @ months , which was a single clinical trial . <eos> we assessed at a @ study of patients in @ hospitals in the <unk> group in a randomized study and the effectiveness of patients who

**random, frozen (control)** (greedy): efficacy of the <unk> and <unk> of the <unk> <unk> ( <unk> ) on the <unk> of the <unk> and <unk> ( <unk> ) . <eos> the primary outcome was the primary outcome of the <unk> and <unk> of the

- sample seed 0: effects of acute treatment and a standard intervention of the intervention of primary patients in a multicentre randomised controlled trial . <eos> we randomly assigned <unk> <unk> ( group @ ) on the intervention and placebo ( n = @
- sample seed 1: effects of three management to the first program program , which for the present population was associated with a lower risk of @ or @ years . <eos> however , the <unk> and safety of the treatment of @ patients
- sample seed 2: effectiveness of <unk> by @ months : <unk> <unk> on a <unk> <unk> ) . <eos> prospective , placebo-controlled , study , patients in @ hospitals of patients ' age in a randomized study and the effectiveness of patients who

**GloVe, trainable (control)** (greedy): efficacy of the <unk> and <unk> of the <unk> and <unk> . <eos> the primary outcome was a significant difference in the control group ( p = @ ) . <eos> the primary outcome was the mean difference in the

- sample seed 0: effects of acute obstructive analgesia . <eos> the primary endpoint was a multicenter fashion that ( n = @ ) and @ patients were randomly allocated to the intervention group . <eos> the intervention was performed ( @ to @
- sample seed 1: effects of the management of the first to assess whether the effects of the <unk> therapy of the knee therapy ( n = @ ) and clinical outcome , and their <unk> and <unk> to investigate the effect of the
- sample seed 2: effectiveness of <unk> intervention and on the use of a single <unk> containing <unk> . <eos> prospective randomized controlled trial was @ patients in @ hospitals in the <unk> group in a randomized study and the acupuncture group , and


## Prompt 2: "patients were randomly assigned to"

**A: random, trainable** (greedy): @ groups , @ % ) . <eos> the primary outcome was the incidence of the <unk> and <unk> ( <unk> ) . <eos> the primary outcome was the incidence of the <unk> and <unk> ( <unk> ) . <eos>

- sample seed 0: receive the control group and a control group ) , @ g ( n = @ ) and or @ ( @ % ci @-@ kg ) . <eos> the primary outcome measure were estimated in the treatment group .
- sample seed 1: @ weeks of the control group . <eos> the intervention group received placebo of the placebo group ( a , n = @ ) . <eos> the primary end point was <unk> was @ weeks of treatment . <eos> the
- sample seed 2: the groups and group @ to @ mg vs. @ ( n = @ ) , group at a follow-up of @ patients in the control group . <eos> this was a significant difference in the <unk> group in the

**B: own skip-gram, frozen** (greedy): receive either a control group ( n = @ ) . <eos> the primary outcome was the proportion of the control group ( @ % ) . <eos> the primary outcome was the proportion of the control group ( @

- sample seed 0: receive the control group and a control group ( @ % ) and the control group . <eos> the patients were randomized to receive either placebo . <eos> group and those on the intervention group ( @ % ) and
- sample seed 1: receive placebo , @ % for a to @ , @ % , @ patients ( @ % ) , or @ ( @ % ) , and @ ( @ % ) , @ % ( @ % )
- sample seed 2: receive @ weeks . <eos> the primary outcome was the differences between baseline and @ min after at @ months , @ patients in the control group . <eos> this was examined the significant difference in baseline and the proportion

**C: GloVe, frozen** (greedy): receive either either a <unk> group ( n = @ ) . <eos> the primary outcome was the proportion of the <unk> group ( @ % ) in the control group ( @ % ) . <eos> the mean of

- sample seed 0: receive the control group and a control group ( @ % daily ) . <eos> the study received the intervention group . <eos> the main end point was not to assess on the intervention and safety ( adjusted to @
- sample seed 1: receive placebo . <eos> a total of @ patients were randomised to placebo of the placebo group ( p > @ ) and or without placebo ( n = @ ) . <eos> the average of the total @ patients
- sample seed 2: receive @ weeks . <eos> the primary outcome was the differences of life was @ min for at @ months , @ patients in the control group . <eos> this was a significant significant difference in baseline ( @/@ )

**random, frozen (control)** (greedy): receive either a <unk> ( n = @ ) or placebo ( n = @ ) . <eos> the primary outcome was the proportion of the <unk> group ( p = @ ) . <eos> the mean difference of the

- sample seed 0: receive the control group and a control group ( @ % daily ) . <eos> the mean treatment was found by @ % were analyzed and @ % were excluded to the intervention group . <eos> the effect of the
- sample seed 1: a placebo : @ % of @ to @ , @ % , respectively , and @ % . <eos> the mean of the average group , whereas @ % of <unk> patients received @ mg ( n = @
- sample seed 2: either @ mg . <eos> the primary endpoint was the intervention group : @ % , p = @ , respectively , and in the control group . <eos> this was a significant difference in the use of patients who

**GloVe, trainable (control)** (greedy): receive either a control group ( n = @ ) . <eos> the primary outcome was the mean change in the control group ( p = @ ) . <eos> the mean change in the control group was @ %

- sample seed 0: receive the control group and a control group ( @ % daily ) . <eos> the study received the intervention group . <eos> median age and @ ( @ % ) on the intervention group ( @ % ) and
- sample seed 1: a placebo group ( n = @ ) . <eos> the difference in the mean range of the follow-up was @ % of @ % and @ % , respectively . <eos> patients received @ mg ( @ % )
- sample seed 2: receive @ mg group @ to @ mg twice daily for the same cycle . <eos> median time of the study was evaluated in @ eyes of the <unk> group in the control group and the baseline group , and


## Prompt 3: "the primary outcome was"

**A: random, trainable** (greedy): the effect of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk> ( @ % ) . <eos> the

- sample seed 0: the rate of treatment and a visual analog factor , but after the treatment that was not related to the first . <eos> the effect of <unk> ( group ) , the intervention were included in the treatment group .
- sample seed 1: a patient effect of a history of age . <eos> the aim of this study was to assess a randomized trial comparing a study involving a clinical study in the phase @ patients , @ to @ weeks , and
- sample seed 2: the patient and safety of life , which was not associated with baseline . <eos> we assessed at a follow-up of @ patients in the control group . <eos> this was a randomized study and the effectiveness of patients who

**B: own skip-gram, frozen** (greedy): the incidence of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and the <unk> of the <unk> . <eos> the primary outcome was the incidence of the <unk> and the <unk> of the

- sample seed 0: assessed the end of the end of the last year , @ months ( @ % ci -rsb- ) , and @ minutes after the first follow-up . <eos> the primary outcome of life measures ( @ ) , and
- sample seed 1: measured by the intention-to-treat . <eos> a total of @ patients enrolled , @ patients had randomly assigned to @ ( @/@ ) or @ mg ( n = @ ) . <eos> the average of the second @ patients
- sample seed 2: used to compare the effect of the <unk> <unk> program ( n = @ ) , and at a @ months of each treatment . <eos> the primary outcome was in @ ( n = @ ) . <eos> participants

**C: GloVe, frozen** (greedy): a significant difference in the <unk> of the <unk> . <eos> the primary outcome was the incidence of the <unk> and the <unk> of the <unk> . <eos> the primary outcome was the incidence of the <unk> and the <unk>

- sample seed 0: assessed . <eos> there were a significant difference in the intervention of the proportion of @ % ( @ % ci @-@ @ , p = @ ) and the use on the intervention group ( @ % ci @-@
- sample seed 1: measured by the intention-to-treat to the first to assess to the rate of the <unk> and <unk> of a <unk> trial . <eos> the primary outcome was significant evidence . <eos> <unk> was significantly greater to the control group and
- sample seed 2: used to compare the effect of the <unk> <unk> on the clinical outcomes . <eos> we assessed at a @ study of patients 's severe care care . <eos> this was a randomized study and the effectiveness of patients who

**random, frozen (control)** (greedy): the effect of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk> . <eos> the primary outcome was the

- sample seed 0: the rate of treatment and a visual analog of the intervention . <eos> the median @ % ( @ % ci @-@ ) were analyzed and @ % were excluded to the intervention group and @ ( @ % ci
- sample seed 1: a significant effect of a difference in the incidence of patients in the control group had no significant difference in the mean of the two groups . <eos> however , mean adverse events , @ % ( @ % )
- sample seed 2: the percentage of death and the other <unk> was not associated with the number of these . <eos> a total of @ patients in @ eyes of patients ' age in a @ week of the <unk> <unk> patients who

**GloVe, trainable (control)** (greedy): the effect of the <unk> and <unk> . <eos> the primary outcome was the mean change in the control group ( p = @ ) . <eos> the mean of @ % of the @ % of the @ %

- sample seed 0: not the differences between the two groups . <eos> the intervention was used for the second <unk> treatment . <eos> these outcome measures were analyzed as <unk> . <eos> the primary outcome measure were estimated in the treatment group .
- sample seed 1: measured by the median number of life . <eos> to determine the association of the <unk> of the intervention , with the same or lower weight scores and @ % of <unk> patients , @ % ( @ % )
- sample seed 2: used to compare the effect of the <unk> <unk> for the <unk> and <unk> . <eos> the intervention consisted of the @ patients in @ eyes of the <unk> group in a standard therapy group ( n = @ )


## Prompt 4: "there was no significant difference in"

**A: random, trainable** (greedy): the incidence of the <unk> and <unk> ( p < @ ) . <eos> the mean difference in the <unk> group was @ % ( @ % ci @-@ @ ) , respectively ( p = @ ) . <eos>

- sample seed 0: the rate of treatment and a visual analog score , @ g ( @ % ci @-@ @ ) , and @ % were analyzed . <eos> in group @ , @ subjects were included in the treatment group .
- sample seed 1: the duration of life ( difference -lsb- p = @ -rsb- for placebo ; p < @ ) . <eos> the mean time was @ years ( p < @ ) . <eos> the average response for total and the
- sample seed 2: the percentage of death and the rate of <unk> use . <eos> the addition of this prospective , controlled trial was to evaluate the impact of a prospective <unk> or a ( @ ) and the effectiveness of patients who

**B: own skip-gram, frozen** (greedy): the two groups . <eos> the primary outcome was the incidence of the <unk> group ( @ % ) in the control group ( p = @ ) . <eos> the primary outcome was the incidence of the <unk> group

- sample seed 0: the the groups between the two groups . <eos> the intervention group ( n = @ ) received the intervention group . <eos> the effect of <unk> ( p < @ ) in the treatment group ( p < @
- sample seed 1: the patient of the control groups . <eos> the present study was the present population was to assess a effect of the of a novel and clinical outcome in the patients with patients who received a <unk> of @ cases
- sample seed 2: the groups and the changes on the <unk> <unk> level ( p = @ ) . <eos> at a follow-up study , there were no significant differences between the groups in the three groups and the effect of patients who

**C: GloVe, frozen** (greedy): the <unk> of the <unk> group . <eos> the mean of the <unk> group was significantly higher in the control group ( p = @ ) . <eos> the mean of the <unk> group was significantly higher in the control

- sample seed 0: the the groups between the control group . <eos> the intervention was registered for the second of treatment or compared with @ minutes of the placebo . <eos> in the study on the intervention and the present of the use
- sample seed 1: the placebo of the control of a significant difference in both postoperative and compared the placebo group . <eos> the trial has significant results in the clinical outcome in the patients with patients who did have not been not not
- sample seed 2: the percentage of death and vomiting , which was not associated with the number of the most groups . <eos> the most common in the control group , <unk> , in a second of @ cases ( @ patients of

**random, frozen (control)** (greedy): the incidence of the <unk> and the control group . <eos> the primary outcome was the incidence of the <unk> and <unk> . <eos> the primary outcome was the incidence of the <unk> and <unk> . <eos> the primary outcome

- sample seed 0: the rate of treatment and a visual analog of the intervention group ( p = @ ) . <eos> our results suggest that the effect of <unk> ( p < @ ) in the treatment of the treatment group .
- sample seed 1: the impact of the control of a significant difference in the difference in the mean analog of the groups . <eos> the median outcome was decreased in the placebo group ( p = @ ) and the total @ %
- sample seed 2: the percentage of death and the rate of the use of the same procedure . <eos> the intervention of the study was to evaluate the effect of the <unk> of two ( bmi ) and the effectiveness of patients who

**GloVe, trainable (control)** (greedy): the control group . <eos> the primary outcome was the mean difference in the control group ( p = @ ) . <eos> the mean of @ % of the @ % of the @ % of the control group

- sample seed 0: the rate of treatment and a reduction in the highest time of the proportion of @ % ( @ % ci @-@ @ , p = @ ) and the use of the intervention group ( @ % ) .
- sample seed 1: the placebo group ( p = @ ) . <eos> the difference in the mean range of the follow-up was similar in the study . <eos> the number of the mean <unk> was @ % of the second @ cases
- sample seed 2: the percentage of death and the rate of life . <eos> the incidence of @ % of @ % of the @ patients in the control group was @ % in the control group and @ % ( @/@ )


## Prompt 5: "these findings suggest that"

**A: random, trainable** (greedy): the effect of the <unk> <unk> ( <unk> ) is a <unk> <unk> ( <unk> ) in the <unk> and <unk> . <eos> the aim of this study was to evaluate the efficacy of a <unk> <unk> ( <unk> )

- sample seed 0: the rate of treatment and a reduction of the <unk> intervention was used for the second . <eos> the patients were randomized to receive either placebo . <eos> group ii had a greater improvement in the same side group and
- sample seed 1: a history of the most program on the incidence of life for the present population was associated with a lower risk of stroke or lower weight , whereas its association of <unk> . <eos> to investigate the effect of the
- sample seed 2: the prevalence of the <unk> system was associated using a single risk of the treatment of <unk> at a follow-up of @ patients in the control group . <eos> this was a randomized study and the effectiveness of patients who

**B: own skip-gram, frozen** (greedy): the effect of the <unk> of the <unk> of the <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk> <unk>

- sample seed 0: the the treatment of treating with a study of the intervention of surgical patients are considered . <eos> the aim of our study was to evaluate the effect of the oral on the intervention and in the treatment group .
- sample seed 1: a effective interventions of a trial . <eos> this , randomised , controlled trial was conducted . <eos> a randomized trial , randomized study involving a clinical population , a phase of @ controlled placebo-controlled trial . <eos> a prospective
- sample seed 2: the aim of this study will to evaluate the efficacy of a novel model to address the influence of a significant improvements between the two groups of the <unk> groups in a randomized clinical trial ( <unk> ) patients who

**C: GloVe, frozen** (greedy): the effect of the <unk> of the <unk> of the <unk> of the <unk> is a effective of the <unk> of the <unk> . <eos> the aim of this study was to evaluate the efficacy of the <unk> of the

- sample seed 0: the the treatment of topical a a significant greater in the incidence of patients that be not related with patients with severe pain were associated with <unk> . <eos> to assess the effectiveness of life in the <unk> group and
- sample seed 1: a <unk> of the most common of the <unk> , <unk> for the present population was associated to a lower risk of pain or lower weight , and its extent of <unk> . <eos> to investigate the effect of the
- sample seed 2: the prevalence of this study on the use of the intervention may be performed . <eos> prospective studies were conducted to compare the incidence of a <unk> <unk> <unk> ( <unk> ) of an <unk> ( <unk> ) patients of

**random, frozen (control)** (greedy): the <unk> of the <unk> <unk> , <unk> , and <unk> , and the <unk> of the <unk> <unk> , and the <unk> of the <unk> <unk> , and the <unk> of the <unk> <unk> , and the <unk> of

- sample seed 0: the the treatment of the study was used to evaluate the hypothesis of the <unk> ( <unk> ) or <unk> ( <unk> ) , we shown <unk> ( intervention ) , on the intervention and safety ( <unk> ) by
- sample seed 1: a randomized controlled trial will be a to assess , randomised , tolerability of the study . <eos> a total of @ patients were randomly assigned to receive @ ( @ ) or placebo @ mg ( n = @
- sample seed 2: the aim of this study were to evaluate the efficacy of a novel <unk> program , <unk> at a @-week study of each 's @ mg of the <unk> or in a randomized study and the effectiveness of patients who

**GloVe, trainable (control)** (greedy): the effect of the <unk> and <unk> <unk> is a effective of the <unk> and <unk> . <eos> the aim of this study was to evaluate the efficacy of the <unk> and <unk> of the <unk> and <unk> in the

- sample seed 0: the benefit of treatment and a standard intervention for the intervention of children receiving chronic hypertension . <eos> the present study was to assess the efficacy of the intervention to assess the effectiveness of a placebo ( <unk> ) by
- sample seed 1: whether the effect of a <unk> vaccine with <unk> , <unk> for the present population was associated with a lower risk of pain or lower weight loss than in the patients with patients who did not affect the association of
- sample seed 2: the importance of the effect of the <unk> was not associated with the number of children . <eos> a total of @ patients in @ eyes of the <unk> or in a standard therapy and the acupuncture group received an

